XBiotech
XBIT
49 hedge funds and large institutions have $35.1M invested in XBiotech in 2016 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 24 increasing their positions, 11 reducing their positions, and 3 closing their positions.
118% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 11
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
10.69% more ownership
Funds ownership: 0% → 10.69% (+11%)
2% more funds holding
Funds holding: 48 → 49 (+1)
19% less capital invested
Capital invested by funds: $43.6M → $35.1M (-$8.5M)
45% less call options, than puts
Call options by funds: $525K | Put options by funds: $952K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.31M |
| 2 |
Goldman Sachs
New York
|
+$798K |
| 3 |
Morgan Stanley
New York
|
+$603K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$431K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$298K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Cadian Capital Management
New York
|
-$1.88M |
| 2 |
UBS AM
Chicago,
Illinois
|
-$183K |
| 3 |
MHS
M Holdings Securities
Portland,
Oregon
|
-$161K |
| 4 |
CG
Cutler Group
San Francisco,
California
|
-$79.5K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$78.8K |
XBIT Hedge Fund Activity: Q4 2016 in Review
49 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q4 2016, worth a combined $35.1M — down 19% from $43.6M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new XBIT positions and 3 closed out — a net gain of 1 holder — while 24 added to existing stakes and 11 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $1.31M. The largest seller was Cadian Capital Management, exiting entirely with an estimated $1.88M sold.
- 49 institutional investors held XBiotech (XBIT) as of Q4 2016, up from 48 in Q3 2016.
- Funds reported $35.1M of XBiotech stock for Q4 2016, down 19% quarter-over-quarter.
- 4 funds opened new XBiotech positions in Q4 2016 and 3 closed out, a net change of +1 holder.
- The largest XBiotech buyer in Q4 2016 was BlackRock Fund Advisors, an estimated $1.31M added.
- The largest XBiotech seller in Q4 2016 was Cadian Capital Management, an estimated $1.88M sold.
Based on aggregated 13F filings for Q4 2016.